Examples of endemic viruses in the United States include those that cause the common cold and the seasonal flu that appear year after year. Much like these, the virus that causes COVID-19 likely won’t die out, and most experts now expect it to become endemic.
We are a team of virologists and immunologists studying animal viruses that infect humans. An essential focus of our research is to identify and describe the key adaptations that animal viruses require to persist in the human population.
Why viruses become endemic
So why did the first SARS virus from 2003 (SARS-CoV) go extinct while this one (SARS-CoV-2) may become endemic?
The ultimate fate of a virus depends on how well it maintains its transmission. Generally speaking, viruses that are highly contagious, meaning that they spread really well from one person to the next, may never die out on their own because they are so good at finding new people to infect.
When a virus first enters a population with no immunity, its contagiousness is defined by scientists using a simple mathematical term, called R0, which is pronounced “R-naught.” This is also referred to as the reproduction number. The reproduction number of a virus represents how many people, on average, are infected by each infected person. For example, the first SARS-CoV had an R0 of about 2, meaning that each infected person passes the virus to two people on average. For the delta variant strain of SARS-CoV-2, the R0 is between 6 and 7.
The goal for public health authorities is to slow the rate by which viruses spread. Universal masking, social distancing, contact tracing and quarantines are all effective tools to reduce the spread of respiratory viruses. Since SARS-CoV was poorly transmissible, it just took a little bit of public health intervention to drive the virus to extinction. Given the highly transmissible nature of the delta variant, the challenge for eliminating the virus will be much greater, meaning that the virus is more likely to become endemic.
Is COVID-19 ever going away?
It’s clear that SARS-CoV-2 is very successful at finding new people to infect, and that people can get infected after vaccination. For these reasons, the transmission of this virus is not expected to end. It’s important that we consider why SARS-CoV-2 moves so easily from one person to the next, and how human behavior plays into that virus transmission.
SARS-CoV-2 is a respiratory virus that is spread through the air and is efficiently transmitted when people congregate. Critical public health interventions, like mask use and social distancing, have been key in slowing the spread of disease. However, any lapse in these public health measures can have dire consequences.
The virus that causes COVID-19 is often associated with superspreading events, in which many people are infected all at once, typically by a single infected individual. In fact, our own work has shown that just 2% of the people infected with COVID-19 carry 90% of the virus that is circulating in a community. These important “supercarriers” have a disproportionately large impact on infecting others, and if they aren’t tracked down before they spread the virus to the next person, they will continue to sustain the epidemic. We currently don’t have a nationwide screening program geared toward identifying these individuals.
Finally, asymptomatically infected people account for roughly half of all infections of COVID-19. This, when coupled with a broad range of time in which people can be infectious – two days before and 10 days after symptoms appear – affords many opportunities for virus transmission, since people who don’t know they are sick generally take few measures to isolate from others.
The contagious nature of SARS-CoV-2 and our highly interconnected society constitute a perfect storm that will likely contribute to sustained virus spread.
What will our future with COVID-19 look like?
Given what we know about COVID-19 so far, many scientists believe that the virus that causes COVID-19 will likely settle into endemic patterns of transmission. But our inability to eradicate the virus does not mean that all hope is lost.
Our post-pandemic future will heavily depend on how the virus evolves over the coming years. SARS-CoV-2 is a completely new human virus that is still adapting to its new host. Over time, we may see the virus become less pathogenic, similar to the four coronaviruses that cause the common cold, which represent little more than a seasonal nuisance.
Global vaccination programs will have the greatest impact on curbing new cases of the disease. However, the SARS-CoV-2 vaccine campaign so far has touched only a small percentage of people on the planet. In addition, breakthrough infections in vaccinated people still occur because no vaccine is 100% effective. This means that booster shots will likely be needed to maximize vaccine-induced protection against infection.
With global virus surveillance and the speed at which safe and effective vaccines have been developed, we are well poised to tackle the ever-evolving target that is SARS-CoV-2. Influenza is endemic and evolves quickly, but seasonal vaccination enables life to go on as normal. We can expect the same for SARS-CoV-2 – eventually.
Four seasonal coronaviruses circulate in humans endemically already. They tend to recur annually, usually during the winter months and affect children more than adults. The virus that causes COVID-19 has not yet settled down into these predictable patterns and instead is flaring up unpredictably around the globe.
Once rates of SARS-CoV-2 stabilize, we can call it endemic. But this transition may look different based on where you are in the world. For instance, countries with high vaccine coverage and plentiful boosters may soon settle into predictable spikes of COVID-19 during the winter months when the environmental conditions are more favorable to virus transmission. In contrast, unpredictable epidemics may persist in regions with lower vaccination rates.
Sara Sawyer is professor of molecular, cellular and developmental biology at the University of Colorado Boulder, Arturo Barbachano-Guerrero is postdoctoral researcher in virology there and Cody Warren is a postdoctoral fellow in virology and immunology there. This piece originally appeared in The Conversation, a nonprofit news source dedicated to unlocking ideas from academia for the public.